Ligand id: 8376

Name: ertugliflozin

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 4
Rotatable bonds 6
Topological polar surface area 108.61
Molecular weight 436.13
XLogP 2.35
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Ertugliflozin was FDA approved to improve glycemic control in adults with type 2 diabetes mellitus (in conjunction with diet and exercise) in December 2017. It was approved as a single agent and in two fixed-dose combination products (Segluromet®, ertugliflozin plus the biguanide metformin, and Steglujan®, ertugliflozin plus the DPP-4 inhibitor sitagliptin).
Mechanism Of Action and Pharmacodynamic Effects
Ertugliflozin inhibits sodium glucose co-transporter-2 (gene symbol SLC5A2), a protein responsible for renal reabsorption of blood glucose. Inhibition of the transporter promotes urinary excretion of glucose [1,3].
External links